Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
483
datasets available to search
ShareScore release 0.9.0
Dataset results
483 results for “Drug therapy”
Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients
ClinicalTrials.gov study NCT00551655. IPD Sharing: Not stated. Countries: 1. Publications: 15.
Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women
ClinicalTrials.gov study NCT04590417. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
ClinicalTrials.gov study NCT01456260. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Guidelines for Drug Therapy of Hypertension: Multi-Site Implementation
ClinicalTrials.gov study NCT00122161. IPD Sharing: Not stated. Countries: 1. Publications: 16.
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer
ClinicalTrials.gov study NCT06261047. IPD Sharing: NO. Countries: 1. Publications: 6.
Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy
ClinicalTrials.gov study NCT03299036. IPD Sharing: NO. Countries: 1. Publications: 2.
Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
ClinicalTrials.gov study NCT00822536. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder
ClinicalTrials.gov study NCT00045903. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Metabolomic and Gut Microbial Biomarkers of Smoking Cessation Treatment in Long-term Drug Therapy: a Randomized Controlled Trial
ClinicalTrials.gov study NCT06803706. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medicat
ClinicalTrials.gov study NCT01455090. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Therapeutic Drug Monitoring and Pharmacogenomics Study of Methadone Therapy
ClinicalTrials.gov study NCT01059747. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Data from: Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients
Open the record for dataset details and reuse information.
Data from: Early antiretroviral therapy and potent second-line drugs could decrease HIV incidence of drug resistance
Early initiation of antiretroviral therapy (ART) reduces the risk of drug-sensitive HIV transmission but may increase the transmission of drug-resistant HIV. We used a mathematical model to estimate the long-term population-level benefits of ART and determine the scenarios under which earlier ART (treatment at 1 year post-infection, on average) could decrease simultaneously both total and drug-resistant HIV incidence (new infections). We constructed an infection-age-structured mathematical model that tracked the transmission rates over the course of infection and modelled the patients' life expectancy as a function of ART initiation timing. We fitted this model to the annual AIDS incidence and death data directly, and to resistance data and demographic data indirectly among men who have sex with men (MSM) in San Francisco. Using counterfactual scenarios, we assessed the impact on total and drug-resistant HIV incidence of ART initiation timing, frequency of acquired drug resistance, and second-line drug effectiveness (defined as the combination of resistance monitoring, biomedical drug efficacy and adherence). Earlier ART initiation could decrease the number of both total and drug-resistant HIV incidence when second-line drug effectiveness is sufficiently high (greater than 80%), but increase the proportion of new infections that are drug resistant. Thus, resistance may paradoxically appear to be increasing while actually decreasing.
Data from: Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion
Objectives: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids for the treatment of macular edema (ME) secondary to central retinal vein occlusion (CRVO). Design: Systematic review and network meta-analysis. Participants: Patients from previously reported randomized controlled trials (RCTs) comparing anti-VEGF and corticosteroids for the treatment of ME secondary to CRVO. Methods: Literature searches were conducted using PubMed, Medline, Embase, Cochrane Library, and clinicaltrials.gov until March 2017. Therapeutic effects were estimated using the proportions of patients gaining/losing ≥15 letters, best-corrected visual acuity (BCVA), and central retinal thickness (CRT). Treatment safety was estimated using the proportions of adverse events, namely increased intraocular pressure (IOP), cataracts, vitreous hemorrhage (VH), and retinal tear. The software ADDIS (version 1.16.8) was used for analysis. Treatment effect and safety of different drugs could be ranked based on simulation. Results: Eleven RCTs comprising 2060 patients were identified. Regarding patients gaining ≥15 letters, aflibercept and ranibizumab were significantly more effective than sham/placebo at 6 months. Regarding patients losing ≥15 letters at 6 months, ranibizumab showed significant improvement compared to dexamethasone. Aflibercept, bevacizumab, or ranibizumab showed greater improvements in BCVA than sham/placebo at 6 months. Intravitreal ranibizumab injection demonstrated greater CRT reduction than both sham and dexamethasone did. Dexamethasone had a higher risk of increased IOP than aflibercept and ranibizumab. Ranibizumab demonstrated a greater risk of cataracts than dexamethasone. Aflibercept and ranibizumab demonstrated low incidence of VH and retinal tear, respectively. Aflibercept had a slight advantage over ranibizumab as assessed by benefit-risk analysis. Conclusions: Anti-VEGF agents have advantages in the treatment of ME secondary to CRVO. Aflibercept and ranibizumab showed marked BCVA improvement and CRT reduction. Aflibercept may have a slight advantage over ranibizumab. The results of this study can serve as a reference for clinicians to provide patient-tailored treatment.
Data from: Development and evaluation of a fluorescent antibody-drug conjugate for molecular imaging and targeted therapy of pancreatic cancer
Antibodies are widely available and cost-effective research tools in life science, and antibody conjugates are now extensively used for targeted therapy, immunohistochemical staining, or in vivo diagnostic imaging of cancer. Significant advances in site-specific antibody labeling technologies have enabled the production of highly characterized and homogenous conjugates for biomedical purposes, and some recent studies have utilized site-specific labeling to synthesize bifunctional antibody conjugates with both imaging and drug delivery properties. While these advances are important for the clinical safety and efficacy of such biologics, these techniques can also be difficult, expensive, and time-consuming. Furthermore, antibody-drug conjugates (ADCs) used for tumor treatment generally remain distinct from conjugates used for diagnosis. Thus, there exists a need to develop simple dual-labeling methods for efficient therapeutic and diagnostic evaluation of antibody conjugates in pre-clinical model systems. Here, we present a rapid and simple method utilizing commercially available reagents for synthesizing a dual-labeled fluorescent ADC. Further, we demonstrate the fluorescent ADC's utility for simultaneous targeted therapy and molecular imaging of cancer both in vitro and in vivo. Employing non-site-specific, amine-reactive chemistry, our novel biopharmaceutical theranostic is a monoclonal antibody specific for a carcinoembryonic antigen (CEA) biomarker conjugated to both paclitaxel and a near-infrared (NIR), polyethylene glycol modified (PEGylated) fluorophore (DyLight™ 680-4xPEG). Using in vitro systems, we demonstrate that this fluorescent ADC selectively binds a CEA-positive pancreatic cancer cell line (BxPC-3) in immunofluorescent staining and flow cytometry, exhibits efficient internalization kinetics, and is cytotoxic. Model studies using a xenograft of BxPC-3 cells in athymic mice also show the fluorescent ADC's efficacy in detecting tumors in vivo and inhibiting tumor growth more effectively than equimolar amounts of unconjugated drug. Overall, our results demonstrate that non-selective, amine-targeting chemistry is an effective dual-labeling method for synthesizing and evaluating a bifunctional fluorescent antibody-drug conjugate, allowing concurrent detection, monitoring and treatment of cancer.
DECISION: Cirrhosis - Overview of existing therapies, drugs & research needs, Pierre-Emmanuel Rautou
<p>https://decision-for-liver.eu/ The objective of the DECISION project is to enhance the understanding of the pathophysiology of decompensation of cirrhosis leading to acute-on-chronic liver failure (ACLF) or death. This consortium will take advantage of already existing large and clinically well-characterized cohorts to ultimately develop prognostic and response tests and combinatorial therapies tailored to the needs of individual patients to decrease the risk of short-term death. In this video, the project's scientific coordinator, Prof. Pierre-Emmanuel Rautou, explains the complications that can occur in cirrhosis patients and how the DECISION project aims to better stratify patients that come to the clinic with acute #decompensation (of #cirrhosis). The goal is to personalise the treatment of individual patients based on tests that can predict the expected #treatment outcome. The video is a recording of the 1st presentation given at an online patient event that was jointly organised by ELPA (https://elpa.eu/) and EF CLIF (https://efclif.com/) and took place on 9th June 2021. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847949. This video reflects only the presenter's view and the European Commission is not responsible for any use that may be made of the information it contains. Production: Beatrice Credi (ELPA) and Dr. Nina Donner (concentris) Subtitles: Nicolas Lupke https://concentris.de © 2021 DECISION Related video about the MICROB-PREDICT project: https://youtu.be/bVjoI1wDUCw Related video about the A-TANGO project: https://youtu.be/5aVZe_CJpps</p>
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
ClinicalTrials.gov study NCT01094886. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
ClinicalTrials.gov study NCT04460937. IPD Sharing: YES. Countries: 1. Publications: 0.
Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
ClinicalTrials.gov study NCT01512446. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
ClinicalTrials.gov study NCT01648023. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.